RADIATION THERAPY ONCOLOGY GROUP
Protocols Closed to Accrual
RTOG 9406
|
A PHASE I/II DOSE ESCALATION STUDY USING
THREE DIMENSIONAL CONFORMAL RADIATION THERAPY
FOR ADENOCARCINOMA OF THE PROSTATE |
RTOG 9311
|
A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL
CONFORMAL RADIATION THERAPY IN PATIENTS WITH INOPERABLE,
NON-SMALL CELL LUNG CANCER |
RTOG 9803
|
PHASE I/II RADIATION DOSE ESCALATION STUDY APPLYING CONFORMAL
RADIATION THERAPY IN SUPRATENTORIAL GLIOBLASTOMA MULTIFORME |
RTOG 0022
|
PHASE I/II STUDY OF CONFORMAL AND INTENSITY MODULATED
IRRADIATION FOR OROPHARYNGEAL CANCER |
RTOG 0117
|
PHASE I/II DOSE INTENSIFICATION STUDY USING THREE
DIMENSIONAL CONFORMAL RADIATION THERAPY AND CONCURRENT CHEMOTHERAPY
FOR PATIENTS WITH INOPERABLE, NON-SMALL CELL LUNG CANCER |
RTOG 0225
|
A PHASE II STUDY OF INTENSITY MODULATED RADIATION
THERAPY (IMRT) +/- CHEMOTHERAPY FOR NASOPHARYNGEAL CANCER |
|
A PHASE II RANDOMIZED TRIAL OF SURGERY FOLLOWED BY
CHEMORADIOTHERAPY PLUS C225 (CETUXIMAB) FOR ADVANCED
SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
|
RTOG 0236
|
A PHASE II TRIAL OF STEREOTACTIC BODY
RADIATION THERAPY (SBRT) IN THE TREATMENT OF PATIENTS WITH
MEDICALLY INOPERABLE STAGE I/II NON-SMALL CELL
LUNG CANCER |
RTOG 0319
|
A PHASE I/II TRIAL TO EVALUATE THREE DIMENSIONAL
CONFORMAL RADIATION THERAPY (3D-CRT) CONFINED TO THE REGION OF
THE LUMPECTOMY CAVITY FOR STAGE I AND IIA BREAST CARCINOMA |
RTOG 0321
|
A PHASE I/II TRIAL OF COMBINED HIGH DOSE RATE
BRACHYTHERAPY AND EXTERNAL BEAM RADIOTHERAPY FOR
ADENOCARCINOMA OF THE PROSTATE |
RTOG 0421 |
A PHASE III TRIAL FOR LOCALLY RECURRENT,
PREVIOUSLY IRRADIATED HEAD AND NECK CANCER:
CONCURRENT RE-IRRADIATION AND CHEMOTHERAPY
VERSUS CHEMOTHERAPY ALONE
|
|
A PHASE II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) ZD 1839
(IRESSA(r)) IN COMBINATION WITH
DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY
IN UNTREATED PATIENTS WITH LOCALLY ADVANCED
CERVICAL CARCINOMA
|
|
A RANDOMIZED, PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF PALIFERMIN (NSC# 740548; IND #6370)
FOR THE REDUCTION OF ORAL MUCOSITIS IN PATIENTS WITH LOCALLY ADVANCED
HEAD AND NECK CANCER RECEIVING RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY (FOLLOWED BY SURGERY FOR SELECTED PATIENTS)
|
|
A COMPARATIVE STUDY OF GROSS TUMOR VOLUME DEFINITION
WITH OR WITHOUT PET FUSION FOR PATIENTS WITH
NON-SMALL CELL LUNG CARCINOMA
|
|
A PHASE II EVALUATION OF DOSE-PAINTED IMRT IN COMBINATION WITH
5-FLUOROURACIL AND MITOMYCIN-C FOR REDUCTION OF ACUTE MORBIDITY
IN CARCINOMA OF THE ANAL CANAL
|